Healius (HLS) Stock Price, News & Analysis

Company Overview

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2.33 million shs
• Average Volume: N/A
• Market Capitalization: $1.01 billion
• P/E Ratio: N/A
• Dividend Yield: 4.46%
• Price Target: N/A
• Consensus Rating: N/A

HLS Stock Analysis - Frequently Asked Questions

How were Healius' earnings last quarter?

Healius Limited (ASX:HLS) posted its quarterly earnings results on Friday, February, 15th. The company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.09 by $0.06. Healius had a negative trailing twelve-month return on equity of 61.77% and a negative net margin of 36.98%.

What other stocks do shareholders of Healius own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Healius investors own include bluebird bio (BLUE), Argonaut Gold (AR), Athene (ATH), BELLUS Health (BLU), Esperion Therapeutics (ESPR), Fortress Biotech (FBIO) and Forte Biosciences (FBRX).

Company Calendar

• Last Earnings: 2/15/2019
• Today: 5/03/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: ASX:HLS
• CIK: N/A
• Web: www.primaryhealthcare.com.au
• Phone: 61 2 9432 9400
• Fax: N/A
• Employees: 10,500
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -0.94
• Net Income: $-636,000,000.00
• Net Margins: -36.98%
• Pretax Margin: N/A
• Return on Equity: -61.77%
• Return on Assets: 1.23%

Debt

• Debt-to-Equity Ratio: 153.54
• Current Ratio: 0.50
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $1.75 billion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 12.26
• Book Value: A$0.88 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 726,130,000
• Free Float: N/A
• Market Cap: $1.01 billion
• Optionable: Not Optionable
• Beta: 0.73